Q3 2025
Released Feb 6, 2025, before the open
10-Q filed Feb 6, 2025, 37 days after period end · 0001764013-25-000026
Q3 2025 · 10-Q
Revenue—
Net Income-$111.12M-$111.12M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.76-$0.76 N/M vs Q3 2024N/M vs Q2 2025
Operating Cash Flowderived-$100,391,000N/M
Free Cash Flowderived-$100,571,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Net Income | -$111.12M | -$51.42M | -$63.23M | -$41.39M |
| EPS Diluted | -$0.76 | -$0.36 | -$0.49 | -$0.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR